NCT06946511View on ClinicalTrials.gov

Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Dementia
Interventions
DRUG

Peptide PMS-001 Intravenous Injection

Participants will receive intravenous injections of PMS-001.

DRUG

Placebo

The control group will receive a placebo, which is the blank excipient (mannitol) of the injectable PMS-001.

Trial Locations (2)

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06946511 - Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia | Biotech Hunter | Biotech Hunter